By Hamza Faisal
University of Leeds spinout adsilico has raised £10 million in a Series A funding round to expand its artificial intelligence platform that tests medical devices on virtual patients before they ever reach a clinical trial. The round was led by PXN Ventures, with existing investors Northern Gritstone and Parkwalk also taking part.
The Leeds-based company, founded in 2024, has built a platform called Virtual Chimera. It uses generative AI to create virtual hearts and blood vessels from anonymised clinical scans, then combines those models with physics-based simulations to show how an implant such as a heart valve or a stent would perform across patient populations that vary in age, sex, ethnicity, body size and medical condition.
Why trials miss so many patients
Clinical trials for medical devices such as heart valves and stents typically involve only a few hundred patients, which makes it hard to represent the diversity of the people who will eventually receive them. Recruiting participants from different demographic groups can also be costly and time-consuming, and the gap shows up in the data: research published in JAMA Internal Medicine found women accounted for just 33 percent of participants across 195 trials of high-risk implants, falling to 29 percent in cardiovascular trials.
“Patients miss out on the chance of a life-saving device, or face uncertainty about whether it will work for them, because people like them weren’t represented when it was designed and tested,” said Sheena Macpherson, adsilico’s chief executive and co-founder. “We give medical device manufacturers early insight into the impact of anatomical diversity when it can still shape the design and help avoid costly mistakes or harm to patients.”
By testing devices on virtual populations first, manufacturers can make earlier decisions about device sizes, identify higher-risk patients and refine their clinical trial strategies. The company positions the platform as additional evidence alongside existing testing methods, helping teams spot potential problems earlier rather than discovering them during a trial.
From heart valves to brain aneurysms
adsilico has already completed projects with heart valve and neurovascular device manufacturers, and its cardiac research is set to be presented at TCT, a meeting focused on innovations in structural heart therapies. The company is based at the university’s Nexus innovation hub and plans to more than double its workforce from 14 to 34 people with the new funding.
That growth will also fund an expansion beyond heart devices into treatments for conditions including brain aneurysms. The company was founded by Macpherson alongside Dr Nishant Ravikumar and Dr Zeike Taylor, and the Series A follows a £3.5 million seed round from Northern Gritstone and Parkwalk that backed its early work on in-silico trials — the use of modelling and simulation to produce evidence about device performance and safety before human testing.
A growing bet on simulated evidence
The funding comes at a moment when virtual testing environments are increasingly recognised as a useful part of medical device development, offering a way to accelerate research while reducing costs and the risks of late-stage failure. Simulations can also reduce reliance on animal testing, an argument that has helped in-silico approaches gain ground with device makers.
Virtual patients do not replace human trials, and adsilico’s pitch is narrower than that: give engineers a far wider and more diverse set of anatomies to test against while a device can still be redesigned cheaply. If that evidence proves reliable, the payoff for manufacturers is fewer surprises in the clinic — and for patients, devices designed with people like them in mind from the start.



